Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Philip Hykin

Showing results (21-30 of 39) with videos related to

Pageof 4
Sort By:
Retina (Philadelphia, Pa.)|March 30, 2021
EFFICACY AND SAFETY OF INTRAVITREAL AFLIBERCEPT USING A TREAT-AND-EXTEND REGIMEN FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: The ARIES Study: A Randomized Clinical TrialPaul Mitchell, Frank G Holz, Philip Hykin, et al.
Ophthalmology. Retina|May 4, 2019
Sustained Benefits from Ranibizumab for Central Retinal Vein Occlusion with Macular Edema: 24-Month Results of the CRYSTAL StudyMichael Larsen, Sebastian M Waldstein, Siegfried Priglinger, et al.
Canadian Journal of Ophthalmology. Journal Canadien D'Ophtalmologie|July 30, 2023
Outcomes of anti-VEGF treatment for macular edema secondary to central retinal vein occlusion in patients with poor baseline visual acuityBahar Demir, Amit Mishra, Maria Pilar Martin Gutierrez, et al.
Ophthalmology. Retina|February 21, 2021
Predictors of Visual Acuity Outcomes after Anti-Vascular Endothelial Growth Factor Treatment for Macular Edema Secondary to Central Retinal Vein OcclusionPiyali Sen, Sarega Gurudas, Jayashree Ramu, et al.
American Journal of Ophthalmology|October 18, 2016
Long-Term Outcomes of Aflibercept Treatment for Neovascular Age-Related Macular Degeneration in a Clinical SettingMaria Eleftheriadou, Clara Vazquez-Alfageme, Cristina Maria Citu, et al.
The Lancet. Diabetes & Endocrinology|March 10, 2018
Clinical efficacy and safety of a light mask for prevention of dark adaptation in treating and preventing progression of early diabetic macular oedema at 24 months (CLEOPATRA): a multicentre, phase 3, randomised controlled trialSobha Sivaprasad, Joana C Vasconcelos, A Toby Prevost, et al.
American Journal of Ophthalmology|December 28, 2016
ReplyMaria Eleftheriadou, Clara Vazquez-Alfageme, Cristina Maria Citu, et al.
Trials|November 24, 2014
A multicentre phase III randomised controlled single-masked clinical trial evaluating the clinical efficacy and safety of light-masks at preventing dark-adaptation in the treatment of early diabetic macular oedema (CLEOPATRA): study protocol for a randomised controlled trialSobha Sivaprasad, Geoffrey Arden, A Toby Prevost, et al.
Lancet (London, England)|May 13, 2017
Clinical efficacy of intravitreal aflibercept versus panretinal photocoagulation for best corrected visual acuity in patients with proliferative diabetic retinopathy at 52 weeks (CLARITY): a multicentre, single-blinded, randomised, controlled, phase 2b, non-inferiority trialSobha Sivaprasad, A Toby Prevost, Joana C Vasconcelos, et al.
Eye (London, England)|January 26, 2020
Ten-year outcomes of antivascular endothelial growth factor therapy in neovascular age-related macular degenerationShruti Chandra, Cristina Arpa, Deepthy Menon, et al.
Pageof 4

Showing results (21-30 of 39) with videos related to

Sort By:
Pageof 4
Retina (Philadelphia, Pa.)|March 30, 2021
EFFICACY AND SAFETY OF INTRAVITREAL AFLIBERCEPT USING A TREAT-AND-EXTEND REGIMEN FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: The ARIES Study: A Randomized Clinical TrialPaul Mitchell, Frank G Holz, Philip Hykin, et al.
Ophthalmology. Retina|May 4, 2019
Sustained Benefits from Ranibizumab for Central Retinal Vein Occlusion with Macular Edema: 24-Month Results of the CRYSTAL StudyMichael Larsen, Sebastian M Waldstein, Siegfried Priglinger, et al.
Canadian Journal of Ophthalmology. Journal Canadien D'Ophtalmologie|July 30, 2023
Outcomes of anti-VEGF treatment for macular edema secondary to central retinal vein occlusion in patients with poor baseline visual acuityBahar Demir, Amit Mishra, Maria Pilar Martin Gutierrez, et al.
Ophthalmology. Retina|February 21, 2021
Predictors of Visual Acuity Outcomes after Anti-Vascular Endothelial Growth Factor Treatment for Macular Edema Secondary to Central Retinal Vein OcclusionPiyali Sen, Sarega Gurudas, Jayashree Ramu, et al.
American Journal of Ophthalmology|October 18, 2016
Long-Term Outcomes of Aflibercept Treatment for Neovascular Age-Related Macular Degeneration in a Clinical SettingMaria Eleftheriadou, Clara Vazquez-Alfageme, Cristina Maria Citu, et al.
The Lancet. Diabetes & Endocrinology|March 10, 2018
Clinical efficacy and safety of a light mask for prevention of dark adaptation in treating and preventing progression of early diabetic macular oedema at 24 months (CLEOPATRA): a multicentre, phase 3, randomised controlled trialSobha Sivaprasad, Joana C Vasconcelos, A Toby Prevost, et al.
American Journal of Ophthalmology|December 28, 2016
ReplyMaria Eleftheriadou, Clara Vazquez-Alfageme, Cristina Maria Citu, et al.
Trials|November 24, 2014
A multicentre phase III randomised controlled single-masked clinical trial evaluating the clinical efficacy and safety of light-masks at preventing dark-adaptation in the treatment of early diabetic macular oedema (CLEOPATRA): study protocol for a randomised controlled trialSobha Sivaprasad, Geoffrey Arden, A Toby Prevost, et al.
Lancet (London, England)|May 13, 2017
Clinical efficacy of intravitreal aflibercept versus panretinal photocoagulation for best corrected visual acuity in patients with proliferative diabetic retinopathy at 52 weeks (CLARITY): a multicentre, single-blinded, randomised, controlled, phase 2b, non-inferiority trialSobha Sivaprasad, A Toby Prevost, Joana C Vasconcelos, et al.
Eye (London, England)|January 26, 2020
Ten-year outcomes of antivascular endothelial growth factor therapy in neovascular age-related macular degenerationShruti Chandra, Cristina Arpa, Deepthy Menon, et al.
Pageof 4